DARATUMUMAB MONOTHERAPY COMPARED WITH REAL-WORLD HISTORICAL CONTROL DATA IN HEAVILY PRETREATED PATIENTS WITH HIGHLY REFRACTORY MULTIPLE MYELOMA: AN ADJUSTED TREATMENT COMPARISON
Author(s): ,
J Diels
Affiliations:
Janssen Health Economics & Market Access EMEA Statistics & Modeling,Beerse,Belgium
,
A Lam
Affiliations:
Janssen Global Services, LLC,Raritan, NJ,United States
,
T Ito
Affiliations:
Janssen Health Economics & Market Access EMEA,High Wycombe,United Kingdom
,
M Mehra
Affiliations:
Janssen Global Services, LLC,Raritan, NJ,United States
I Khan
Affiliations:
Janssen Research & Development, LLC,Raritan, NJ,United States
(Abstract release date: May 19, 2016) EHA Learning Center. Diels J. Jun 9, 2016; 132812
Label: Abstracts 2016
Disclosure(s): Employee of Janssen Health Economics & Market Access EMEA Statistics & Modeling
Joris Diels
Joris Diels

Access to EHA Members only content is an EHA membership benefit.
Click here to join EHA or renew your membership here.


Abstract
Discussion Forum (0)
Rate & Comment (0)
Abstract: E1263

Type: Eposter Presentation

Background
Daratumumab (DARA) received FDA approval in November 2015 based on data from single-arm phase 2 studies, following fast track/breakthrough therapy designation based on preliminary clinical evidence showing substantial improvements over available therapy for the treatment of heavily pretreated/refractory patients with multiple myeloma (MM). Recent analyses of pooled DARA studies and real-world US data revealed median overall survival (OS) of 19.9 (95% confidence interval [CI], 15.1-not evaluable) months and 7.9 (95% CI, 6.9-8.9) months in heavily pretreated and refractory patients with MM, respectively (Usmani S, et al. Blood. 2015;126(23): Abstract 4498 and Usmani S, et al. Blood. 2015;126(23): Abstract 29). In the absence of randomized head-to-head trials, evidence on the relative treatment efficacy of DARA versus physician’s choice (PC) based on an adjusted comparison of data from a single arm trial versus a historical control group of comparable patients can inform the decisions of both clinicians and payers.

Aims
To estimate the comparative efficacy of DARA, as measured by overall survival, versus real-world historical control (PC) based on a comparison of data from DARA monotherapy clinical studies versus real-world US data, adjusted for confounding factors between patient cohorts.

Methods
Patient-level data were pooled from DARA monotherapy clinical studies (patients treated with DARA 16 mg/kg in the SIRIUS and GEN501 studies) and from two independent US databases (IMS-LifeLink and OPTUM), which reflect treatments utilized in a real-world cohort of patients with MM who received at least 3 prior therapy lines or were double refractory to a proteasome inhibitor and immunomodulatory drug. Using a multivariate proportional hazards regression model, the relative treatment effect of DARA compared with PC was estimated, adjusting for imbalances in patient characteristics between patient cohorts; co-variates included gender, age, albumin, hemoglobin, number of prior therapies, prior pomalidomide/carfilzomib-exposure, and refractory status.

Results
Baseline characteristics that differed between patients treated with DARA (N=148) and the real-world US historical control (N=658) included median age (64 vs 69 y), median lines of prior therapy (5 vs 4), prior treatment with pomalidomide (55% vs 15%) and carfilzomib (41% vs 28%), and triple/quadruple refractory status (64% vs 14%). The adjusted OS-hazard ratio (HR) for DARA versus PC was 0.32 (95% CI, 0.22-0.46) compared with 0.44 (95% CI, 0.33-0.58) for unadjusted HR. The impact of adjustment was mainly driven by differences in refractory status and prior exposure to pomalidomide/carfilzomib.

Conclusion
This adjusted treatment comparison suggests that DARA demonstrates improved OS compared with real-world historical control data in heavily pretreated and refractory MM patients. Such comparisons allow evaluation of novel agents in the absence of head-to-head comparison studies.

Session topic: E-poster

Keyword(s): Multiple myeloma
Code of conduct/disclaimer available in General Terms & Conditions